4,476 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Scissortail Wealth Management LLC

Scissortail Wealth Management LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 4,476 shares of the company’s stock, valued at approximately $863,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Diversified Portfolios Inc. acquired a new position in Zoetis in the 4th quarter valued at $203,000. Everence Capital Management Inc. raised its holdings in shares of Zoetis by 31.7% during the 4th quarter. Everence Capital Management Inc. now owns 17,900 shares of the company’s stock worth $3,533,000 after buying an additional 4,310 shares in the last quarter. First American Trust FSB raised its holdings in shares of Zoetis by 2.6% during the 4th quarter. First American Trust FSB now owns 45,423 shares of the company’s stock worth $8,965,000 after buying an additional 1,150 shares in the last quarter. Capital Analysts LLC raised its holdings in shares of Zoetis by 1.5% during the 4th quarter. Capital Analysts LLC now owns 51,332 shares of the company’s stock worth $10,131,000 after buying an additional 739 shares in the last quarter. Finally, Keel Point LLC raised its holdings in shares of Zoetis by 7.3% during the 4th quarter. Keel Point LLC now owns 2,173 shares of the company’s stock worth $429,000 after buying an additional 148 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Up 2.2 %

Shares of NYSE ZTS traded up $3.25 during trading on Wednesday, reaching $153.02. The company had a trading volume of 4,967,617 shares, compared to its average volume of 3,610,045. The company’s fifty day moving average price is $178.25 and its 200-day moving average price is $180.59. Zoetis Inc. has a 12 month low of $148.48 and a 12 month high of $201.92. The stock has a market cap of $69.99 billion, a P/E ratio of 30.18, a PEG ratio of 2.29 and a beta of 0.85. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The business had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.15 earnings per share. As a group, research analysts expect that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.13%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is 34.12%.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the transaction, the executive vice president now directly owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 2,209 shares of company stock valued at $408,453. Company insiders own 0.15% of the company’s stock.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research analyst reports. The Goldman Sachs Group boosted their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Barclays boosted their price objective on Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Stifel Nicolaus reduced their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Jefferies Financial Group restated a “buy” rating and set a $230.00 price objective on shares of Zoetis in a research report on Tuesday, December 19th. Finally, StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and an average target price of $221.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.